ARTICLE | Product Development
Diamedica shows early efficacy in preeclampsia — an indication starved for innovation
DM199 lowered blood pressure and improved uterine blood flow, marking rare progress in a condition with no approved therapies and a tiny pipeline
July 18, 2025 12:26 AM UTC
In a rare win for women’s health, Diamedica reported interim Phase II preeclampsia data that suggests improved blood supply to the pregnant person and fetus. The next milestone will be prolonging pregnancy.
Diamedica Therapeutics Inc. (NASDAQ:DMAC), which currently has the most advanced program for preeclampsia, announced Wednesday that DM199, a recombinant form of the KLK1 protein, reduced both systolic and diastolic blood pressure in pregnant women in Part Ia of a Phase II study...
BCIQ Company Profiles